007IC - Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider

Friday, April 28, 2023

10:00 AM – 12:00 PM CST

Location: S102C

Instructional Course Director(s)

CL

Costas Lallas, MD

Professor of Urology
Thomas Jefferson University Hospital

Instructional Course Faculty(s)

Anne Lizardi-Calvaresi, DNP (she/her/hers)

Director of Clinical Operations
Thomas Jefferson University
ET

Edouard Trabulsi, MD,MBA (he/him/his)

Professor and Chair, Dept of Urology
Albert Einstein Medical Center

Course Description: Review of advanced and metastatic prostate, bladder and kidney cancer. Most recent treatment guidelines are reviewed along with the studies that support them. Different disease spaces in oncologic care are discussed, including the medications used to treat them, their mechanism, side effects and efficacy. Role of the advanced practice provider is discussed for each tumor type. Finally, cases are presented along with management options for audience participation.

Learning Objectives:

Recall the guidelines for first-line and beyond treatment of patients with hormone-sensitive metastatic prostate cancer, including medications, their mechanism, side effects and efficacy.
Recall the guidelines for first-line and beyond treatment of patients with castrate-resistant nonmetastatic prostate cancer, including medications, their mechanism, side effects and efficacy.
Recall the guidelines for first-line and beyond treatment of patients with castrate-resistant metastatic prostate cancer, including medications, their mechanism, side effects and efficacy.
Recall the guidelines for first-line and beyond treatment of patients with metastatic bladder cancer, including medications, their mechanism, side effects and efficacy.
Recall the guidelines for first-line and beyond treatment of patients with metastatic kidney cancer, including medications, their mechanism, side effects and efficacy.